A Treat-and-Extend Regimen of Intravitreal Brolucizumab for Exudative Age-Related Macular Degeneration Refractory to Aflibercept: A 12-Month Result

We aimed to investigate whether a treat-and-extend regimen of intravitreal brolucizumab (6.0 mg/0.05 mL) is effective for eyes with exudative age-related macular degeneration (AMD) refractory to aflibercept for 12 months. Sixty eyes from 56 patients receiving brolucizumab for exudative AMD refractor...

Full beskrivning

Bibliografiska uppgifter

Huvudupphov:	Wataru Kikushima, Yoichi Sakurada, Yoshiko Fukuda, Mio Matsubara, Yumi Kotoda, Atsushi Sugiyama, Kenji Kashiwagi
Materialtyp:	Artigo
Språk:	Inglês
Utgiven:	MDPI AG 2023-04-01
Serie:	Pharmaceuticals
Ämnen:	age-related macular degeneration polypoidal choroidal vasculopathy intravitreal brolucizumab injection treat-and-extend switching
Länkar:	https://www.mdpi.com/1424-8247/16/4/562
Taggar:	Lägg till en tagg Inga taggar, Lägg till första taggen!